# South America iPS Cell Derived Organoids Market > South America iPS Cell-derived Organoids Market Research Report By Type (Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids, Others), By Application (Drug Discovery and Development, Disease Modelling, Regenerative Medicine), By End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organization) and By Region (Brazil, Mexico, Argentina, Rest of South America) -Forecast to 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 17.54% - **2024:** $ 40.8 Million - **2025:** $ 47.96 Million - **2035:** $ 241.4 Million - **Key Players:** Organovo Holdings Inc (US), Stemcell Technologies Inc (CA), Cellectis SA (FR), Asterias Biotherapeutics Inc (US), Regenative Labs LLC (US), TissUse GmbH (DE), InSphero AG (CH), Hesperos Inc (US), Eindhoven University of Technology (NL) **Report ID:** MRFR/LS/51626-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-america-ips-cell-derived-organoids-market-53387 --- ## Market Summary ## **South America****iPS****Cell-derived Organoids Market****Overview** As per MRFR analysis, the South America iPS cell-derived organoids marketsize was estimated at 44 (USD million) in 2023.The South America iPS cell-derived organoids marketis expected to grow from 51(USD million) in 2024 to 309 (USD million) by 2035. The South America iPS cell-derived organoids marketCAGR (growth rate) is expected to be around 17.795% during the forecast period (2025-2035). **Key****South America****iPS****cell-derived organoids market****Trends Highlighted** The South America iPS cell-derived organoids market is witnessing significant growth driven by advancements in regenerative medicine and stem cell research. The increasing focus on personalized medicine and drug development in countries like Brazil and Argentina is propelling the demand for innovative research tools such as organoids, which can model human diseases more effectively. Additionally, rising investments by both public and private sectors in biotechnology and life sciences are enabling better access to cutting-edge technologies. Government initiatives supporting scientific research also contribute to enhancing local capabilities in developing iPS cell-derived organoids, further augmenting this market. Opportunities lie in enhancing collaborations between academic institutions and biotechnology companies to foster innovation in organoid applications. South America has a rich biodiversity, which can be leveraged to develop unique organoid models. Furthermore, as more researchers and institutions in the region recognize the potential of stem cell-derived models for drug screening and disease modeling, the market remains poised for expansion. Recent trends include a growing interest in applying organoids in developing therapies for diseases prevalent in the region, such as tropical diseases, thereby addressing local health challenges. In recent times, there has been a notable shift towards sustainable and ethical approaches in stem cell research, which resonates with the increasing awareness and regulatory frameworks addressing ethical concerns in countries like Colombia and Chile. This focus not only supports market growth but also aligns with the global movement towards responsible research practices. With these driving forces and emerging opportunities, the South America iPS cell-derived organoids market is expected to evolve, connecting local innovations with global advancements in biotechnology. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **South America****iPS****Cell-derived Organoids Market****Drivers** **Growing Investment in Stem Cell Research** In South America, there has been a notable increase in government and private sector funding for research and development (R&D) in stem cell research and regenerative medicine. For instance, countries like Brazil and Argentina have initiated significant grants and funding programs to support breakthroughs in stem cell technologies, which includes iPS cell-derived organoids. The Brazilian government, through its National Council for Scientific and Technological Development, increased its funding for research projects by 30% over the last five years. This investment not only supports innovative scientific research but also aids in the establishment of infrastructures that can enhance the capabilities of the South America iPS cell-derived organoids market, potentially leading to advancements in personalized medicine, disease modeling, and drug development. Additionally, collaborations with established organizations like the Latin American Society for Stem Cell Research are on the rise, further promoting R&D in this field. **Rising Incidence of Chronic Diseases** The prevalence of chronic diseases, including cancer and heart disease, is significantly contributing to the growth of the South America iPS cell-derived organoids market. According to the Pan American Health Organization, cancer cases are projected to increase by approximately 7% by 2030 in several South American countries. **Advancements in Biotechnology** The biotechnology sector in South America is rapidly evolving, thanks to technological advancements in biomanufacturing and bioinformatics. A report from the Chamber of Biotechnology in Uruguay indicates that the sector has seen a growth of 25% in new biotech startups over the past three years. These advancements have catalyzed the research and application of iPS cell-derived organoids, making it easier for researchers to develop and utilize these innovative technologies for drug discovery and development.Collaborations with international biotech firms, such as those emerging from partnerships between local universities and global companies like Synthego, are expected to propel the South America iPS cell-derived organoids market forward, enhancing the production and accessibility of organoid technologies. **South America****iPS****Cell-derived Organoids Market****Segment Insights** **iPS****Cell-Derived Organoids****M****arket****Type Insights** iPS cell-derived market becoming increasingly essential in research and clinical applications. Brain organoids stand out due to their critical role in understanding neurological disorders and brain development; they provide a valuable platform for drug testing and disease modeling, reflecting the growing emphasis on personalized medicine in South America. Heart organoids have gained traction for their significance in cardiovascular disease research and regenerative therapies, which aligns with the increasing prevalence of heart conditions in the region, opening doors for innovative treatment strategies.Lung organoids are vital in studying respiratory diseases, including chronic conditions and viral infections, directly addressing public health concerns that are particularly relevant given the recent global health challenges faced by South America. Liver organoids are pivotal for their applications in drug metabolism studies and liver disease modeling, which is essential in a region that grapples with high incidences of liver-related ailments. Kidney Organoids also play a significant role, especially in understanding renal pathologies as well as in the development of nephroprotective therapies, enhancing the viability of kidney health interventions. encompass various organoids that cater to less represented but equally crucial areas of research, fostering advancements in organ-on-a-chip technology and multi-organ systems modeling. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **iPS****Cell-****d****erived Organoids****M****arket****Application Insights** The South America iPS cell-derived organoids market is characterized by its diverse applications which play a crucial role in various fields of biomedicine. The drug discovery and development application is significant due to the growing demand for more effective pharmaceutical solutions, allowing researchers to model human diseases and assess drug responses without extensive animal testing. Disease modelling is another key area, offering the ability to mimic human conditions more accurately, which streamlines the understanding of disease mechanisms and potential therapeutic targets. Regenerative medicine stands out as a critical application as it harnesses the potential of iPS cell-derived organoids to repair and regenerate damaged tissues, addressing major health challenges faced in the region. With the increasing focus on innovative healthcare solutions, South America is likely to witness substantial engagement in these applications, fostering advancements that are aligned with global trends in personalized medicine and enhanced patient outcomes. **iPS****Cell-****d****erived Organoids****M****arket****End User Insights** The end user segment of the South America iPS cell-derived organoids market plays a critical role in shaping the landscape of biomedicine and regenerative research in the region. Pharmaceutical and biotechnology companies are among the primary users, leveraging these organoids for drug discovery and preclinical testing, thus streamlining the development process and enhancing therapeutic outcomes. Academic and research institutes significantly contribute to the advancement of scientific knowledge by utilizing these organoids for fundamental research and innovative studies, addressing diseases prevalent in South America. Contract research organizations serve as vital partners, offering essential services that facilitate the use of iPS cell-derived organoids for various experimental studies, enabling companies and institutes to focus on their core competencies. The growing interest in personalized medicine and the need for effective drug-testing models further emphasize the importance of this segment. **iPS****Cell-****d****erived Organoids****M****arket****Regional Insight****s** The South America iPS cell-derived organoids market reflects a burgeoning sector, particularly driven by advancements in regenerative medicine and biomedical research. Brazil holds a significant position in the market, benefiting from its robust research and development initiatives and a growing number of biotechnological enterprises focused on organoid applications. Mexico, with increasing investment in life sciences and a rising number of clinical trials, also plays a crucial role in the regional landscape. Argentina presents a unique opportunity, as its academic institutions are actively engaged in innovative research pertaining to stem cell technologies and organoid functionalities. Rest of South America gaining momentum due to collaborative efforts in scientific research across various countries, the growing interest in these technologies, exemplifying the region's commitment to advancing healthcare solutions. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **South America****iPS****C****ell-derived****Organoids Market****Key Players and Competitive Insights** The South America iPS cell-derived organoids market is experiencing significant growth, driven by advancements in regenerative medicine and the increasing prevalence of chronic diseases. The competitive landscape in this region features a blend of established companies and emerging players working towards innovative solutions that harness the potential of induced pluripotent stem cells. This market is characterized by robust research and development activities, aimed at expanding the applications of organoids in drug development, disease modeling, and personalized medicine. As stakeholders strive to create strategic partnerships and collaborations, the competitive insights underscore a dynamic environment focused on delivering advanced therapeutic options to healthcare providers and researchers across South America. Stemcell Technologies has a prominent presence in the South America iPS cell-derived organoids market, showcasing its commitment to advancing stem cell research and application. The company offers a wide range of innovative cell culture products and services, tailored specifically for generating and maintaining organoids derived from iPS cells. Its strong reputation in the scientific community is rooted in the high quality and reliability of its products, which have facilitated numerous breakthroughs in cell biology research. Additionally, Stemcell Technologies actively engages with local scientific institutions and researchers, fostering collaborations that enhance their market presence and contribute to the overall development of organoid technologies in the region. Their emphasis on education and training further solidifies their role as a key player in advancing stem cell research. Organogenesis is another influential entity in the South America iPS cell-derived organoids market, recognized for its cutting-edge regenerative medicine solutions that leverage the unique capabilities of organoids. The company provides a suite of products and services, including sophisticated cell cultures and organoid-based technologies designed to meet the specific needs of the South American healthcare landscape. With a strong emphasis on innovation, Organogenesis has positioned itself as a forward-thinking player in the market. The company actively pursues strategic partnerships and collaborations with local hospitals and research institutions, further enhancing its market presence. In recent years, Organogenesis has also engaged in mergers and acquisitions, which have bolstered its capabilities and broadened its portfolio of offerings related to iPS cell-derived organoids. Their dedication to advancing medical science through collaborative efforts contributes significantly to their strengths within the South American market, enabling them to address a variety of healthcare challenges effectively. **Key Companies in the****South America****iPS****C****ell-derived****Organoids Market****Include** - Stemcell Technologies - Organogenesis - Roche - Takara Bio - Cellarpay - Crown Bioscience - Thermo Fisher Scientific - Lonza - Ncardia - 3D Biotek - Corning - Axol Bioscience - Merck KGaA - Asterias Biotherapeutics - InSphero **South America****iPS****C****ell-derived****Organoids Market****Developments** The South America iPS cell-derived organoids market has seen significant recent developments, reflecting increasing interest in regenerative medicine and advanced research applications. Companies like Stemcell Technologies, Roche, Takara Bio, and Thermo Fisher Scientific are expanding their portfolios, focusing on innovative organoid technologies to support drug testing and disease modeling. The region's market growth is evident with rising investments in biotechnology and academic research initiatives, leading to a stronger collaborative environment. In October 2023, Roche announced a partnership with local biotechnology firms to enhance capabilities in organoid research, which is expected to bolster product offerings. Additionally, Asterias Biotherapeutics has recently expanded its operations in Brazil, aiming to tap into the growing demand for advanced cell therapies. As of March 2023, Cellarpay and Organogenesis reported on their collaborative projects related to regenerative medicine applications, underlining the industry's thriving landscape. While no major mergers or acquisitions have been publicly announced during this period, the overall valuation and market presence of key players like Lonza, Corning, and Merck KGaA are seeing positive trends, impacting the overall dynamics of the iPS Cell-Derived Organoids market in South America. **South America****iPS****C****ell-derived****Organoids Market****Segmentation Insights** **iPS****Cell-****d****erived Organoids****M****arket****Type****Outlook** - Brain Organoids - Heart Organoids - Lung Organoids - Liver Organoids - Kidney Organoids - Others **iPS****Cell-****d****erived Organoids****M****arket****Application****Outlook** - Drug Discovery and Development - Disease Modelling - Regenerative Medicine **iPS****Cell-****d****erived Organoids****M****arket****End User****Outlook** - Pharmaceutical and Biotechnology Companies - Academic and Research Institutes - Contract Research Organization **iPS****Cell-Derived Organoids****M****arket****Regional****Outlook** - Brazil - Mexico - Argentina - Rest of South America ## Market Drivers ### Advancements in Stem Cell Research Recent advancements in stem cell research are significantly influencing the ips cell-derived-organoids market in South America. Breakthroughs in understanding stem cell biology and differentiation processes have led to the development of more sophisticated organoid models. These models are increasingly being utilized in drug discovery, toxicity testing, and disease modeling. Countries like Argentina and Chile are at the forefront of this research, with numerous institutions focusing on stem cell applications. The market for stem cell therapies is projected to grow substantially, potentially reaching $1.5 billion by 2027 in South America. This growth is likely to create a favorable environment for the ips cell-derived-organoids market, as researchers and clinicians seek to leverage these advancements for therapeutic purposes. ### Rising Prevalence of Chronic Diseases The escalating prevalence of chronic diseases in South America is a significant driver for the ips cell-derived-organoids market. Conditions such as diabetes, cancer, and cardiovascular diseases are becoming increasingly common, necessitating innovative research and treatment approaches. Ips cell-derived organoids offer a promising platform for studying disease mechanisms and testing new therapies. According to recent statistics, chronic diseases account for nearly 70% of all deaths in the region, highlighting the urgent need for effective treatment solutions. This growing health crisis is likely to enhance the demand for organoid technology, as researchers seek to develop more effective and targeted therapies using ips cell-derived organoids. ### Growing Demand for Personalized Medicine The increasing emphasis on personalized medicine in South America is driving the ips cell-derived-organoids market. As healthcare systems evolve, there is a notable shift towards treatments tailored to individual patient profiles. This trend is supported by advancements in genomics and biotechnology, which enable the development of organoids that closely mimic human physiology. The market for personalized medicine is projected to reach approximately $2 billion by 2026 in South America, indicating a robust growth trajectory. This demand for customized therapeutic solutions is likely to propel the ips cell-derived-organoids market, as these organoids can be utilized for drug testing and disease modeling, thereby enhancing treatment efficacy and safety. ### Increased Funding for Regenerative Medicine In South America, there is a marked increase in funding directed towards regenerative medicine, which significantly impacts the ips cell-derived-organoids market. Governments and private investors are recognizing the potential of stem cell research and organoid technology in addressing chronic diseases and injuries. For instance, Brazil has allocated substantial resources to research initiatives aimed at developing innovative therapies using ips cell-derived organoids. This influx of capital is expected to foster advancements in organoid technology, leading to improved applications in drug discovery and disease modeling. The regenerative medicine market in South America is anticipated to grow at a CAGR of around 15% over the next five years, further stimulating the ips cell-derived-organoids market. ### Collaborative Efforts in Research and Development Collaborative efforts among academic institutions, government agencies, and private companies are fostering innovation in the ips cell-derived-organoids market in South America. These partnerships are essential for sharing knowledge, resources, and expertise, which can accelerate the development of organoid technologies. For example, joint research initiatives between universities and biotech firms are increasingly common, leading to the creation of advanced organoid models for various applications. Such collaborations are expected to enhance the overall research landscape, driving the market forward. The collaborative research funding in the region is projected to increase by approximately 20% over the next few years, indicating a strong commitment to advancing the ips cell-derived-organoids market. ## Future Outlook The [IPS Cell Derived Organoids Market](https://www.marketresearchfuture.com/reports/ips-cell-derived-organoids-market-28623) is projected to grow at a 17.54% CAGR from 2025 to 2035, driven by advancements in regenerative medicine, drug discovery, and personalized therapies. **New opportunities:** - Development of tailored organoid models for specific diseases - Partnerships with pharmaceutical companies for drug testing - Investment in biobanking for organoid research and development By 2035, the market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Type: Brain Organoids (Largest) vs. Kidney Organoids (Fastest-Growing) In the current market landscape, Brain Organoids lead as the largest segment within the Type category, garnering substantial interest due to their application in neurological studies. Following closely behind are Lung and Liver Organoids, which also contribute significantly to the overall market share. Kidney Organoids, while smaller in share, are developing rapidly as researchers explore their potential in kidney disease modeling and drug testing. The growth trends in the organoid segment are influenced by advancements in regenerative medicine and personalized therapy approaches. With increasing funding and support for research initiatives, Kidney Organoids, in particular, are witnessing a surge in interest and application, marking them as the fastest-growing segment. Sustained innovations in technologies that support organoid development are key drivers of expansion in this sector. Brain Organoids (Dominant) vs. Kidney Organoids (Emerging) Brain Organoids are currently the dominant player in the organoid market, showcasing extensive applications in neuroscience, drug discovery, and disease modeling. Their intricate structure closely mimics human brain tissue, making them invaluable for studying neurological disorders. On the other hand, Kidney Organoids represent an emerging segment with rapid growth potential, driven by their operational relevance in therapeutic research and transplantation science. These organoids facilitate in-depth studies of kidney diseases and toxicology assessments, positioning them as essential tools in both academic and pharmaceutical research. As demand grows for more sophisticated in vitro models, both segments are poised for continued development and innovation. ### By Application: Drug Discovery and Development (Largest) vs. Regenerative Medicine (Fastest-Growing) In the South America ips cell-derived-organoids market, Drug Discovery and Development currently holds the largest market share. This segment benefits from its crucial role in the pharmaceutical industry, where organoids are used to model complex human biology, significantly enhancing the efficiency of drug testing. Meanwhile, the Disease Modelling segment also plays a substantial role, but it does not surpass the dominance of Drug Discovery and Development in terms of market share distribution. Looking ahead, Regenerative Medicine is poised to emerge as the fastest-growing segment, driven by an increasing need for innovative therapeutic solutions for chronic diseases and injuries. The ongoing advancements in stem cell technologies, alongside rising healthcare expenditures in South America, are key factors fueling growth. Furthermore, collaborations between academic institutions and biotech companies are expected to propel research and development in this area, positioning Regenerative Medicine as a pivotal opportunity for investment and innovation. Disease Modelling (Dominant) vs. Regenerative Medicine (Emerging) Disease Modelling is a dominant segment characterized by its essential function in research and understanding of various diseases. It utilizes ips cell-derived-organoids to replicate disease conditions accurately, which aids in drug testing and the exploration of disease mechanisms. This segment has established its importance among research institutions and biotechnology firms, providing invaluable insights that facilitate drug development processes. On the other hand, Regenerative Medicine is emerging as a vital segment, fueled by innovative approaches to repair and regenerate damaged tissues. This growth is supported by technological advancements and a shift towards personalized medicine, making it an exciting area of development. The synergy of these two segments is driving advancements in therapeutic strategies across the medical landscape. ### By End User: Pharmaceutical and Biotechnology Companies (Largest) vs. Contract Research Organization (Fastest-Growing) In the South America ips cell-derived-organoids market, the distribution among end users highlights the significant share held by pharmaceutical and biotechnology companies, which dominate the landscape. These companies rely heavily on advanced organoid technologies for drug discovery and development, driving substantial demand in the market. Conversely, contract research organizations, while smaller in overall share, are experiencing rapid growth as they offer specialized services that appeal to many biotech firms looking for external support. Growth trends indicate that pharmaceutical and biotechnology companies will continue to harness innovation in ips cell technology to streamline research processes and enhance therapeutic discovery. Meanwhile, contract research organizations are emerging as strategic partners for these firms, buoyed by the increased need for outsourcing in drug development. The accelerating pace of biopharmaceutical advancements in South America signals a bright future for both segments, with technological innovation playing a pivotal role in their evolution. Pharmaceutical and Biotechnology Companies (Dominant) vs. Contract Research Organization (Emerging) Pharmaceutical and biotechnology companies represent the dominant force in the South America ips cell-derived-organoids market, leveraging their extensive resources and established infrastructures to integrate cell-derived organoids into their research and development workflows. These firms focus on translating innovative science into therapeutic applications, which has led to significant investment in organoid technologies. On the other hand, contract research organizations are emerging players within this space, specializing in providing essential services to biopharmaceutical companies. They offer capabilities ranging from preclinical testing to expert consultation, appealing to smaller biotech ventures with limited capabilities. As the demand for efficient drug development processes grows, these organizations are well-positioned to capture market opportunities and foster collaborations that enhance their visibility and relevance. ## Regional Market Share Analysis ### Brazil : Strong Growth and Innovation Hub São Paulo and Rio de Janeiro are pivotal markets, hosting numerous biotech firms and research institutions. The competitive landscape features major players like Organovo Holdings Inc and Stemcell Technologies Inc, which have established a strong presence. The local market dynamics are characterized by a collaborative environment between academia and industry, fostering innovation in drug development and regenerative medicine applications. ### Mexico : Growing Demand and Investment Trends Key markets include Mexico City and Guadalajara, where several biotech startups are emerging. The competitive landscape features companies like Cellectis SA and Asterias Biotherapeutics Inc, which are expanding their operations. The local business environment is favorable, with increasing collaborations between universities and industry, particularly in regenerative medicine and cancer research. ### Argentina : Focus on Research and Development Buenos Aires and Córdoba are key markets, hosting several research institutions and biotech companies. The competitive landscape includes players like Regenative Labs LLC and TissUse GmbH, which are exploring local partnerships. The business environment is characterized by a supportive academic community and increasing interest in organoid applications for drug discovery and toxicology testing. ### Rest of South America : Potential for Growth and Innovation Key markets include Santiago and Bogotá, where emerging biotech firms are starting to establish themselves. The competitive landscape is less saturated, providing opportunities for new entrants. Local dynamics are evolving, with a focus on collaborations between universities and industry to drive innovation in healthcare applications, particularly in drug development and regenerative therapies. ## Competitive Benchmarking The ips cell-derived-organoids market in South America exhibits a dynamic competitive landscape characterized by rapid innovation and strategic collaborations. Key growth drivers include advancements in regenerative medicine, increasing investment in biotechnology, and a growing emphasis on personalized medicine. Major players such as Organovo Holdings Inc (US), Stemcell Technologies Inc (CA), and Cellectis SA (FR) are at the forefront, each adopting distinct strategies to enhance their market positioning. Organovo Holdings Inc (US) focuses on pioneering 3D bioprinting technologies, while Stemcell Technologies Inc (CA) emphasizes the development of specialized cell culture media and reagents. Cellectis SA (FR) is leveraging its gene-editing capabilities to create organoids that can model complex diseases, thereby enhancing its competitive edge in the market.The business tactics employed by these companies reflect a concerted effort to optimize operations and enhance market presence. Localizing manufacturing and optimizing supply chains are prevalent strategies aimed at reducing costs and improving responsiveness to market demands. The competitive structure of the market appears moderately fragmented, with several players vying for market share, yet the influence of key players is substantial, shaping the overall direction of the industry. In October Organovo Holdings Inc (US) announced a strategic partnership with a leading South American research institution to develop organoid models for drug testing. This collaboration is poised to enhance the company's research capabilities and expand its footprint in the region, potentially leading to innovative solutions in drug discovery and development. The strategic importance of this partnership lies in its potential to accelerate the translation of research into clinical applications, thereby positioning Organovo as a leader in the market. In September Stemcell Technologies Inc (CA) launched a new line of organoid culture systems specifically designed for South American researchers. This initiative not only demonstrates the company's commitment to regional needs but also enhances its product offerings, allowing for greater customization and flexibility in research applications. The launch is significant as it aligns with the growing demand for tailored solutions in the biotechnology sector, potentially increasing market penetration. In August Cellectis SA (FR) secured a substantial investment to further its research on gene-edited organoids. This funding is expected to bolster its R&D efforts, particularly in developing organoids that can mimic human diseases more accurately. The strategic importance of this investment lies in its potential to accelerate innovation and enhance the company's competitive positioning in the rapidly evolving market. As of November current competitive trends indicate a strong focus on digitalization, sustainability, and the integration of artificial intelligence in research and development processes. Strategic alliances are increasingly shaping the landscape, fostering collaboration between academia and industry. Looking ahead, competitive differentiation is likely to evolve, shifting from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition underscores the importance of agility and responsiveness in meeting the evolving needs of the market. ## Recent News & Developments The South America iPS cell-derived organoids market has seen significant recent developments, reflecting increasing interest in regenerative medicine and advanced research applications. Companies like Stemcell Technologies, Roche, Takara Bio, and Thermo Fisher Scientific are expanding their portfolios, focusing on innovative organoid technologies to support drug testing and disease modeling. The region's market growth is evident with rising investments in biotechnology and academic research initiatives, leading to a stronger collaborative environment. In October 2023, Roche announced a partnership with local biotechnology firms to enhance capabilities in organoid research, which is expected to bolster product offerings. Additionally, Asterias Biotherapeutics has recently expanded its operations in Brazil, aiming to tap into the growing demand for advanced cell therapies. As of March 2023, Cellarpay and Organogenesis reported on their collaborative projects related to regenerative medicine applications, underlining the industry's thriving landscape. While no major mergers or acquisitions have been publicly announced during this period, the overall valuation and market presence of key players like Lonza, Corning, and Merck KGaA are seeing positive trends, impacting the overall dynamics of the iPS Cell-Derived Organoids market in South America. **South America****iPS****C****ell-derived****Organoids Market****Segmentation Insights** **iPS****Cell-****d****erived Organoids****M****arket****Type****Outlook** - Brain Organoids - Heart Organoids - Lung Organoids - Liver Organoids - Kidney Organoids - Others **iPS****Cell-****d****erived Organoids****M****arket****Application****Outlook** - Drug Discovery and Development - Disease Modelling - Regenerative Medicine **iPS****Cell-****d****erived Organoids****M****arket****End User****Outlook** - Pharmaceutical and Biotechnology Companies - Academic and Research Institutes - Contract Research Organization **iPS****Cell-Derived Organoids****M****arket****Regional****Outlook** - Brazil - Mexico - Argentina - Rest of South America ## Report Scope | MARKET SIZE 2024 | 40.8(USD Million) | | --- | --- | | MARKET SIZE 2025 | 47.96(USD Million) | | MARKET SIZE 2035 | 241.4(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 17.54% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Organovo Holdings Inc (US), Stemcell Technologies Inc (CA), Cellectis SA (FR), Asterias Biotherapeutics Inc (US), Regenative Labs LLC (US), TissUse GmbH (DE), InSphero AG (CH), Hesperos Inc (US), Eindhoven University of Technology (NL) | | Segments Covered | Type, Application, End User | | Key Market Opportunities | Growing demand for personalized medicine drives innovation in the ips cell-derived-organoids market. | | Key Market Dynamics | Rising investment in Research and Development for innovative applications of induced pluripotent stem cell-derived organoids in South America. | | Countries Covered | Brazil, Mexico, Argentina, Rest of South America | ## Frequently Asked Questions **Q: What is the projected market valuation for the South America ips cell-derived-organoids market by 2035?** A: The projected market valuation for the South America ips cell-derived-organoids market by 2035 is $241.4 Million. **Q: What was the market valuation in 2024 for the South America ips cell-derived-organoids market?** A: The market valuation in 2024 for the South America ips cell-derived-organoids market was $40.8 Million. **Q: What is the expected CAGR for the South America ips cell-derived-organoids market during the forecast period 2025 - 2035?** A: The expected CAGR for the South America ips cell-derived-organoids market during the forecast period 2025 - 2035 is 17.54%. **Q: Which segment is projected to have the highest valuation in the South America ips cell-derived-organoids market by 2035?** A: The Drug Discovery and Development segment is projected to have the highest valuation, reaching $88.0 Million by 2035. **Q: What are the key players in the South America ips cell-derived-organoids market?** A: Key players in the market include Organovo Holdings Inc, Stemcell Technologies Inc, and Cellectis SA, among others. **Q: How much is the Brain Organoids segment expected to be valued at by 2035?** A: The Brain Organoids segment is expected to be valued at $48.84 Million by 2035. **Q: What is the projected valuation for the Liver Organoids segment by 2035?** A: The projected valuation for the Liver Organoids segment by 2035 is $46.08 Million. **Q: Which end user segment is anticipated to dominate the market by 2035?** A: The Pharmaceutical and Biotechnology Companies segment is anticipated to dominate the market, with a projected valuation of $121.0 Million by 2035. **Q: What is the expected valuation for the Disease Modelling application by 2035?** A: The expected valuation for the Disease Modelling application by 2035 is $70.0 Million. **Q: How does the market valuation in 2024 compare to the projected valuation in 2035?** A: The market valuation in 2024 was $40.8 Million, which indicates substantial growth to a projected $241.4 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-america-ips-cell-derived-organoids-market-53387*